H35.3114 Nonexudative age-related macular degeneration, right eye, advanced atrophic with subfoveal involvement

Name of the Condition

• Nonexudative Age-Related Macular Degeneration, Right Eye, Advanced Atrophic with Subfoveal Involvement

Summary

Nonexudative age-related macular degeneration (AMD) is a chronic eye condition affecting the macula, the central part of the retina responsible for sharp central vision. It is characterized by gradual macular deterioration without fluid leakage or bleeding, leading to blurred or reduced vision. This form is commonly referred to as "dry AMD." The advanced atrophic stage with subfoveal involvement involves significant thinning of the retinal pigment epithelium and photoreceptors in the macula, particularly under the fovea, resulting in notable vision loss.

Causes

The exact cause of nonexudative AMD is not fully understood, but it involves the degeneration of retinal cells and the accumulation of drusen (yellow deposits) under the retina. Oxidative stress and inflammation in retinal tissues are also believed to contribute to the condition.

Risk Factors

• Increasing age, especially over 50.
• Family history of macular degeneration.
• Smoking and tobacco use.
• Obesity and high cholesterol.
• Lack of exercise and poor diet lacking antioxidants and zinc.

Symptoms

• Blurred or reduced central vision in the right eye.
• Difficulty recognizing faces or reading.
• Need for brighter lighting when working or reading.
• Haziness in overall vision.

Diagnosis

Diagnosis involves a comprehensive eye examination, including dilation, to assess the macula. Optical coherence tomography (OCT) is used to visualize retinal layers and detect atrophic changes, while an Amsler grid test may reveal central vision distortions. Fluorescein angiography or fundus autofluorescence imaging can help confirm subfoveal involvement and advanced atrophy.

Treatment Options

Treatment focuses on managing symptoms and slowing progression. Nutritional supplements (e.g., vitamins C, E, zinc, and lutein) may be recommended. Low-vision aids, such as magnifiers or specialized lighting, can assist with daily tasks. In some cases, anti-VEGF therapy may be considered if neovascularization (wet AMD) develops.

Prognosis and Follow-Up

Prognosis depends on the extent of atrophy and subfoveal involvement, with advanced stages often leading to permanent central vision loss. Regular follow-up with an ophthalmologist is essential to monitor for progression or complications, such as the development of wet AMD.

Complications

• Permanent central vision loss.
• Difficulty with activities requiring sharp vision (e.g., reading, driving).
• Increased risk of developing neovascular (wet) AMD in the same or fellow eye.

Lifestyle & Prevention

• Quit smoking and avoid tobacco exposure.
• Maintain a balanced diet rich in antioxidants and omega-3 fatty acids.
• Exercise regularly to support overall health.
• Protect eyes from excessive UV light with sunglasses.
• Monitor vision changes using an Amsler grid at home.

When to Seek Professional Help

Seek immediate medical attention if you experience sudden vision changes, such as blurriness, distortion, or dark spots, as these may indicate progression to wet AMD or other serious conditions.

Tips for Medical Coders

Document the specific stage (advanced atrophic) and subfoveal involvement to support accurate coding. Include details of diagnostic tests (e.g., OCT findings) and any treatment interventions. Ensure the right eye is clearly specified, as this impacts code assignment.